Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 475-481

  Berezin, A E ^a   Kremzer, A A ^a  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Artery calcification; Asymptomatic atherosclerosis; Osteopontin; Predicted value; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OSTEOPONTIN;

ADULT; AGATSTON SCORE; ARTICLE; BLOOD SAMPLING; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 84880588435     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.06.003     Document Type: Article

References (32)

1. Levy D. Combating the epidemic of heart disease. JAm Med Assoc 2012 Dec 26, 308(24):2624-2625.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Otton J.M., Lønborg J.T., Boshell D., Feneley M., Hayen A., Sammel N., et al. Amethod for coronary artery calcium scoring using contrast-enhanced computed tomography. JCardiovasc Comput Tomogr 2012, 6:37-44.
4. Greenland P., LaBree L., Azen S.P., Doherty T.M., Detrano R.C. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAm Med Assoc 2004, 291:210-215.
5. Polonsky T.S., McClelland R.L., Jorgensen N.W., Bild D.E., Burke G.L., Guerci A.D., et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAm Med Assoc 2010, 303:1610-1616.
6. Erbel R., Mohlenkamp S., Moebus S., Schmermund A., Lehmann N., Stang A., et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall Study. JAm Coll Cardiol 2010, 56:1397-1406.
7. Budoff M.J., Young R., Lopez V.A., Kronmal R.A., Nasir K., Blumenthal R.S., et al. Progression of coronary calcium and incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis. JAm Coll Cardiol 2013, 61(12):1231-1239.
8. Lund S.A., Wilson C.L., Raines E.W., Tang J., Giachelli C.M., Scatena M. Osteopontin mediates macrophage chemotaxis via α(4) and α(9) integrins and survival via the α(4) integrin. JCell Biochem 2013, 114(5):1194-1202.
9. Bishop E., Theophilus E.H., Fearon I.M. Invitro and clinical studies examining the expression of osteopontin in cigarette smoke-exposed endothelial cells and cigarette smokers. BMC Cardiovasc Disord 2012 Sep 17, 12:75.
10. Zheng Y., Wang Z., Deng L., Yuan X., Ma Y., Zhang G., et al. Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells. Eur J Immunol 2012, 42(10):2803-2814.
11. Jiménez-Corona A.E., Damián-Zamacona S., Pérez-Torres A., Moreno A., Mas-Oliva J. Osteopontin upregulation in atherogenesis is associated with cellular oxidative stress triggered by the activation of scavenger receptors. Arch Med Res 2012 Feb, 43(2):102-111.
12. Gao H., Steffen M.C., Ramos K.S. Osteopontin regulates α-smooth muscle actin and calponin in vascular smooth muscle cells. Cell Biol Int 2012, 36(2):155-161.
13. Tousoulis D., Siasos G., Maniatis K., Oikonomou E., Kioufis S., Zaromitidou M., et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2012, http://dx.doi.org/10.1016/j.ijcard.2012.05.001.
14. Abdel-Azeez H.A., Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. JClin Lab Anal 2010, 24(3):201-206.
15. Georgiadou P., Iliodromitis E.K., Kolokathis F., Varounis C., Gizas V., Mavroidis M., et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest 2010 Apr, 40(4):288-293.
16. Wendelin-Saarenhovi M., Oikonen M., Loo B.M., Juonala M., Kähönen M., Viikari J.S., et al. Plasma osteopontin is not associated with vascular markers of subclinical atherosclerosis in a population of young adults without symptoms of cardiovascular disease. The Cardiovascular Risk in Young Finns Study. Scand J Clin Lab Invest 2011, 71(8):683-689.
17. Sun J., Xu Y., Dai Z., Sun Y. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol Cell Endocrinol 2009, 313(1-2):64-69.
18. Ishiyama M., Suzuki E., Katsuda J., Murase H., Tajima Y., Horikawa Y., et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009, 85(2):189-196.
19. Momiyama Y., Ohmori R., Fayad Z.A., Kihara T., Tanaka N., Kato R., et al. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis 2010, 210(2):668-670.
20. Gardin J.M., Adams D.B., Douglas P.S., Feigenbaum H., Forst D.H., Fraser A.G., et al. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. JAm Soc Echocardiogr 2002, 15:275-290. American Society of Echocardiography.
21. Bluemke D.A., Achenbach S., Budoff M., Gerber T.C., Gersh B., Hillis L.D., et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Circulation 2008, 118:586-606.
22. Agatston A.S., Janowitz W.R. Ultrafast computed tomography in coronary screening. Circulation 1994, 89(4):1908-1909.
23. Budoff M.J., Achenbach S., Blumenthal R.S., Carr J.J., Goldin J.G., Greenland P., et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006, 114:1761-1791. Intervention AHACoCIa, Intervention AHACoCRa, American Heart Association Committee on Cardiac Imaging CoCCIntervention AHACoCRa, American Heart Association Committee on Cardiac Imaging CoCC.
24. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. JAm Coll Cardiol 1990, 15(4):827-832.
25. Gabbasov Z.A., Agapov A.A., Saburova O.S., Komlev A.E., Soboleva E.L., Akchurin R.S., et al. Circulating stromal osteonectin-positive progenitor cells and stenotic coronary atherosclerosis. Can J Physiol Pharmacol 2007, 85(3-4):295-300.
26. Tousoulis D., Siasos G., Maniatis K., Oikonomou E., Vlasis K., Papavassiliou A.G., et al. Novel biomarkers assessing the calcium deposition in coronary artery disease. Curr Med Chem 2012, 19(6):901-920.
27. Laframboise W.A., Dhir R., Kelly L.A., Petrosko P., Krill-Burger J.M., Sciulli C.M., et al. Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med 2012, 10(1):157.
28. Würtz P., Raiko J.R., Magnussen C.G., Soininen P., Kangas A.J., Tynkkynen T., et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J 2012, 33(18):2307-2316.
29. Juonala M., Magnussen C.G., Venn A., Gall S., Kähönen M., Laitinen T., et al. Parental smoking in childhood and brachial artery flow-mediated dilatation in young adults: the Cardiovascular Risk in Young Finns Study and the Childhood Determinants of Adult Health Study. Arterioscler Thromb Vasc Biol 2012, 32(4):1024-1031.
30. Hernesniemi J.A., Seppälä I., Lyytikäinen L.P., Mononen N., Oksala N., Hutri-Kähönen N., et al. Genetic profiling using genome - wide significant coronary artery disease risk variants does not improve the prediction of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study, the Bogalusa Heart Study and the Health 2000 Survey - a meta-analysis of three independent studies. PLoS One 2012, 7(1):e28931.
31. Mansikkaniemi K., Juonala M., Taimela S., Hirvensalo M., Telama R., Huupponen R., et al. Cross-sectional associations between physical activity and selected coronary heart disease risk factors in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med 2012, 44(7):733-744.
32. Magnussen C.G., Koskinen J., Chen W., Thomson R., Schmidt M.D., Srinivasan S.R., et al. Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study. Circulation 2010, 122(16):1604-1611.